Download Image
    
Share
  
Post
Apremilast for COVID-19
2 studies with >500 patients
Hospital Icon Control
Hospital Icon Apremilast Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Apremilast studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -3% Mortality -3% Recovery -19% RCTs -3% RCT mortality -3% Late -3% Favorsapremilast Favorscontrol
Nov 8
2024
 Xie et al., Cellular & Molecular Biology Letters, doi:10.1186/s11658-024-00659-6 The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death
Review of the effects of reactive oxygen species (ROS) on cell death pathways in SARS-CoV-2 infection. SARS-CoV-2 induces oxidative stress and ROS generation which can lead to several types of regulated cell death including NETosis, ferro..
Mar 3
2023
 Files et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.101889 Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
5% higher mortality (p=0.85) and 28% worse recovery (p=0.22). RCT severe COVID-19 patients showing no significant difference in outcomes with apremilast.
Apr 7
2022
 Amgen, NCT04590586 Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
1% higher mortality (p=1), 8% worse improvement (p=0.73), 11% lower hospital discharge (p=0.56), and 11% worse recovery (p=0.58). RCT 384 hospitalized patients showing no significant difference with apremilast treatment.